SLXNW · Silexion Therapeutics Ltd.

This filing reflects a coordinated corporate action package designed to enhance Silexion Therapeutics Corp’s capital structure flexibility and long-term equity compensation framework. The authorized share capital increase—adding 50 million ordinary shares—directly expands the company’s ability to issue equity for strategic purposes, including potential future financings, acquisitions, or partnerships, without requiring additional shareholder approvals. The Evergreen Increase Proposal significantly broadens the annual share reserve under the 2024 Equity Incentive Plan, shifting from a fixed 5% of issued shares to a dynamic 10% of fully diluted shares; this change strengthens retention and recruitment capabilities amid competitive biotech talent markets and aligns equity grants more closely with long-term dilution management. The approved 1-for-10 reverse share split addresses structural market considerations: it raises the nominal share price, potentially improving eligibility for Nasdaq listing standards—including minimum bid price and public float thresholds—and may enhance institutional investor appeal by reducing share count and increasing per-share metrics. All proposals were approved by narrow but clear majorities (61.3–61.4% in favor) among the 40.2% of issued shares represented—a quorum established under the Articles’ procedural provision after a 30-minute delay. The simultaneous effectiveness of the Memorandum Amendment on May 5, 2026, underscores execution discipline, though implementation of the reverse split remains contingent on Nasdaq compliance verification. Collectively, these actions signal proactive governance aimed at positioning the company for scalability and market readiness.